Innoviva Share Holder Equity 2010-2024 | INVA
Innoviva share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Innoviva Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$675 |
| 2022 |
$566 |
| 2021 |
$526 |
| 2020 |
$608 |
| 2019 |
$342 |
| 2018 |
$159 |
| 2017 |
$-243 |
| 2016 |
$-353 |
| 2015 |
$-343 |
| 2014 |
$-223 |
| 2013 |
$299 |
| 2012 |
$155 |
| 2011 |
$-87 |
| 2010 |
$-22 |
| 2009 |
$-189 |
Innoviva Quarterly Share Holder Equity
(Millions of US $) |
| 2024-09-30 |
$669 |
| 2024-06-30 |
$666 |
| 2024-03-31 |
$704 |
| 2023-12-31 |
$675 |
| 2023-09-30 |
$627 |
| 2023-06-30 |
$555 |
| 2023-03-31 |
$561 |
| 2022-12-31 |
$566 |
| 2022-09-30 |
$641 |
| 2022-06-30 |
$565 |
| 2022-03-31 |
$552 |
| 2021-12-31 |
$526 |
| 2021-09-30 |
$492 |
| 2021-06-30 |
$394 |
| 2021-03-31 |
$697 |
| 2020-12-31 |
$608 |
| 2020-09-30 |
$535 |
| 2020-06-30 |
$493 |
| 2020-03-31 |
$406 |
| 2019-12-31 |
$342 |
| 2019-09-30 |
$284 |
| 2019-06-30 |
$247 |
| 2019-03-31 |
$200 |
| 2018-12-31 |
$159 |
| 2018-09-30 |
$-108 |
| 2018-06-30 |
$-155 |
| 2018-03-31 |
$-213 |
| 2017-12-31 |
$-243 |
| 2017-09-30 |
$-223 |
| 2017-06-30 |
$-297 |
| 2017-03-31 |
$-334 |
| 2016-12-31 |
$-353 |
| 2016-09-30 |
$-368 |
| 2016-06-30 |
$-363 |
| 2016-03-31 |
$-362 |
| 2015-12-31 |
$-343 |
| 2015-09-30 |
$-323 |
| 2015-06-30 |
$-294 |
| 2015-03-31 |
$-260 |
| 2014-12-31 |
$-223 |
| 2014-09-30 |
$-193 |
| 2014-06-30 |
$-188 |
| 2014-03-31 |
$263 |
| 2013-12-31 |
$299 |
| 2013-09-30 |
$330 |
| 2013-06-30 |
$86 |
| 2013-03-31 |
$92 |
| 2012-12-31 |
$155 |
| 2012-09-30 |
$173 |
| 2012-06-30 |
$189 |
| 2012-03-31 |
$6 |
| 2011-12-31 |
$-87 |
| 2011-09-30 |
$-59 |
| 2011-06-30 |
$-37 |
| 2011-03-31 |
$-28 |
| 2010-12-31 |
$-22 |
| 2010-09-30 |
$-141 |
| 2010-06-30 |
$-126 |
| 2010-03-31 |
$-113 |
| 2009-12-31 |
$-189 |
| 2009-09-30 |
$-175 |
| 2009-06-30 |
$-159 |
| 2009-03-31 |
$-144 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
